尿道周围与阴道内雌激素预防复发性尿路感染 (TAPER)
尿道周围与阴道内雌激素预防复发性尿路感染:TAPER(应用阴道雌激素预防复发性尿路感染的技术)试验
Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of which is the safe and efficacious option of vaginal estrogen therapy. Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week, but some providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral area. This ideally reduces the amount of vaginal estrogen used while attaining a similar effect. However, to date, there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Pennsylvania
-
Cranberry Township、Pennsylvania、美国、16066
- UPMC Lemieux Sports Complex
-
Erie、Pennsylvania、美国、16550
- UPMC Hamot
-
Pittsburgh、Pennsylvania、美国、15213
- University of Pittsburgh Medical Center-Magee Womens Hospital
-
Pittsburgh、Pennsylvania、美国、15237
- UPMC Passavant-McCandless
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Postmenopausal (definition: No menses for 1 or more years or surgical menopause (bilateral oophorectomy). If there is a past history of hysterectomy, patient must be age 56 or older (95th percentile for age at menopause) or have laboratory evidence of menopause (ie. FSH >30)
- Meets criteria for recurrent urinary tract infections (UTIs) with 2 or more UTI in 6 months or 3 or more UTI in 1 year
- May include patients who used vaginal estrogen previously if they have stopped use for 3 or more months prior to inclusion into study.
- Patients must be recommended vaginal estrogen as part of normal clinical care for prevention of recurrent UTI
Exclusion Criteria:
- Current use of vaginal or oral estrogen products
- Inability or refusal to use vaginal estrogen
- Daily antibiotic use
- Significant vaginal stenosis (eg. due to lichen sclerosis, radiation or obliterative prolapse surgery) that would prohibit use of a vaginal applicator (ie. genital hiatus <1cm)
- Inability to use vaginal applicator and without caregiver who can administer (eg. provider-managed pessary use, significant arthritis)
- Frequent (1x weekly or more frequent) use of bladder instillations containing an antibiotic
- Known hydronephrosis as a result of incomplete bladder emptying
- Use of intermittent or indwelling urinary catheterization
- Known bladder stones, mesh erosion into bladder, or foreign object in bladder
- Unable to consent for self
- Active treatment for an estrogen-dependent malignancy
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Intravaginal Estrogen Application
Intravaginal application of 1 gram estradiol cream at bedtime twice a week for 6 months |
The control group will apply 1 gram estradiol cream intravaginally using an applicator. |
|
实验性的:Periurethral Estrogen Application
Periurethral application of 0.5 gram estradiol cream at bedtime twice a week for 6 months |
The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants Who Are UTI-free at 6 Months
大体时间:6 months
|
The primary outcome was the percentage of participants who were UTI-free at 6 months after study drug initiation. |
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Urinary Symptoms at 6 Months
大体时间:Baseline, 6 months
|
Questionnaire assessment of urinary symptoms and symptom distress (Urogenital Distress Inventory, Short Form), total score range 0-100 with higher numbers representing worse urinary symptoms |
Baseline, 6 months
|
|
Change From Baseline in Sexual Function at 6 Months
大体时间:Baseline, 6 months
|
Questionnaire assessment of sexual function (Female Sexual Function Index-6) with scores ranging from 2 to 30, with 19 and below denoting sexual dysfunction. |
Baseline, 6 months
|
|
Change From Baseline in Vaginal pH at 6 Months
大体时间:Baseline, 6 months
|
Assessment using pH strips during pelvic examination |
Baseline, 6 months
|
|
Participant Experience With Study Drug
大体时间:6 months
|
Agreement with the statement: "I am satisfied with the estrogen cream." (Positive response of "agree" or "strongly agree" on 5-point Likert Scale) |
6 months
|
|
Vaginal Maturation Value
大体时间:3 months
|
Vaginal maturation value at 3 months (score 0-100, higher values correlating with greater vaginal estrogenization) |
3 months
|
|
Average Amount of Estrogen Used Per Tube
大体时间:6 months
|
Study drug tubes were weighed at baseline and then at follow-up visits (weight in grams) and the average amount of study drug used per tube was calculated. |
6 months
|
|
Percentage of Participants With Lactobacillus Crispatus Positive Vaginal Specimens
大体时间:6 months
|
Lactobacillus crispatus is a species of Lactobacillus known to assist with UTI prevention through the maintenance of an acidic environment. It generally is elevated in the vagina in the presence of estrogen. |
6 months
|
|
Percentage of Participants With E. Coli Positive Vaginal Specimens
大体时间:6 months
|
E. coli is a common uropathogen and thus was investigated in the pilot translational sub-aim of this research study. |
6 months
|
合作者和调查者
调查人员
- 首席研究员:Stephanie W Zuo, MD、University of Pittsburgh Medical Center
出版物和有用的链接
一般刊物
- Zuo SW, Bradley M, Mowers EE, Zyczynski HM, Hillier SL, Ackenbom MF. Periurethral versus intravaginal application of vaginal estrogen for the prevention of urinary tract infections in postmenopausal women: Design of a randomized non-inferiority trial. Contemp Clin Trials. 2025 Jun;153:107893. doi: 10.1016/j.cct.2025.107893. Epub 2025 Mar 30.
- Zuo SW, Mowers EE, Hem S, Bradley M, Zyczynski HM, Hillier SL, Ackenbom MF. Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial. Obstet Gynecol. 2026 Jul 27. doi: 10.1097/AOG.0000000000006376. Online ahead of print.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- STUDY22010147
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.